TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2897986

Group type: EXPERIMENTAL
Intervention: 120 mg of terfenadine and 300 mg of flurbiprofen per day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Terfenadine and a placebo that looked like flurbiprofen
Number of subjects: 28
Study: 31619442

Group type: EXPERIMENTAL
Intervention: Berberine 900 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Berberine and mesalamine
Number of subjects: 16
Study: 30212239

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/day)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Tiotropium (5 μg/day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: No add-on therapy
Number of subjects: 87
Study: 28751960

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 1765

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 1765
Study: 26071277

Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose (300 mg or 900 mg)
Number of subjects: 106
Study: 23668548

Group type: EXPERIMENTAL
Intervention: Nebulized cyclosporine (300 mg of CIS, 62.5 mg/mL CsA in propylene glycol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulized cyclosporine with predose coaching
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulized cyclosporine (300 mg of CIS)
Number of subjects: 10
Study: 22610907

Group type: EXPERIMENTAL
Intervention: Supervised exercise, 3 times per week for 6 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: General advice about physical activity (Control)
Number of subjects: 140
Study: 18831711

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 17572575

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg intravenously intraoperatively followed by a 6-day oral tapering dose of methyl-prednisone)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arnica (three times a day for 4 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (received neither agent)
Number of subjects: 48
Study: 15769535

Group type: EXPERIMENTAL
Intervention: Unidirectional articulation in UHMWPE acetabular components
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multidirectional articulation in UHMWPE acetabular components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient gait path analysis
Number of subjects: 0
Study: 12034149

Group type: EXPERIMENTAL
Intervention: Chronic atrial fibrillation (AF)
Number of subjects: 60
Study: 9846713

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cystectomy
Number of subjects: 44
Study: 7740468

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low molecular weight heparin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin plus 100 mg aspirin
Number of subjects: 24
Study: 3190989

Group type: EXPERIMENTAL
Intervention: Trimethoprim, 200 mg twice daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Cephalexin, 250 mg four times daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 77
Study: 29514551

Group type: EXPERIMENTAL
Intervention: Perpetration items only
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Perpetration items followed by victimization items
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Victimization items followed by perpetration items
Number of subjects: 179

Group type: COMPARATOR
Intervention: Victimization items only
Number of subjects: 179
Study: 31845149

Group type: EXPERIMENTAL
Intervention: Younger Hispanic/Latino and black men having older sex partners (≥50% of partners being at least 5 years older)
Number of subjects: 2665

Group type: EXPERIMENTAL
Intervention: Not knowing one's HIV status
Number of subjects: 2665

Group type: EXPERIMENTAL
Intervention: Having a black sex partner
Number of subjects: 2665
Study: 29382793

Group type: EXPERIMENTAL
Intervention: Frequent monitoring (immediately after intubation, every 8 h, and when clinically indicated)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Infrequent monitoring (immediately after intubation and when clinically indicated)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Frequent monitoring
Number of subjects: 305

Group type: COMPARATOR
Intervention: Infrequent monitoring
Number of subjects: 305
Study: 28865897

Group type: EXPERIMENTAL
Intervention: Drug Eluting Stents (DES)
Number of subjects: 4626

Group type: COMPARATOR
Intervention: Bare Metal Stents (BMS)
Number of subjects: 4626
Study: 26559572

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy plus PCI (PCI group)
Number of subjects: 2287

Group type: COMPARATOR
Intervention: Optimal medical therapy alone (medical‐therapy group)
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: Both groups (PCI and medical therapy)
Number of subjects: 2287
Study: 24333824

Group type: EXPERIMENTAL
Intervention: Relaxation group (RG); 12×150 minutes sessions: standard intervention + relaxation techniques
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG); 12×90 minutes weekly sessions: psychoeducational group intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Relaxation group (RG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study: 21402444

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18928089

Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (modified Jiawei Danggui Decection + 10 mg Loratadine tablet, once daily) for 4 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional Western medicine (10 mg Loratadine tablet, once daily) for 4 weeks
Number of subjects: 47
Study: 16724174

Group type: EXPERIMENTAL
Intervention: High frequency (HF) rTMS over the right dorsolateral prefrontal cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo sham condition
Number of subjects: 0
Study: 12580913

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized extract for 4-5 years
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (drug therapy only)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 60
Study: 10781473

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8622611

Group type: EXPERIMENTAL
Intervention: Thalassemia major patients (anti-HCV-negative)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Thalassemia major patients (anti-HCV-positive)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Patients with hepatic cirrhosis
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All patient groups (TM and cirrhosis)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Thalassemia major patients
Number of subjects: 29
Study: 1595847

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with pethidine 25 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.1875% bupivacaine with pethidine 25 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with pethidine 25 mg
Number of subjects: 60
Study: 6397971

Group type: EXPERIMENTAL
Intervention: +cyanidanol-3
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 29728331

Group type: COMPARATOR
Intervention: 30 mg MDMA plus psychotherapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 75 mg MDMA plus psychotherapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 125 mg MDMA plus psychotherapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Open-label crossover with full-dose MDMA (100-125 mg) after 30 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Open-label crossover with full-dose MDMA (100-125 mg) after 75 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All groups after full-dose MDMA (100-125 mg) at 12-month follow-up
Number of subjects: 26
Study: 27858074

Group type: EXPERIMENTAL
Intervention: Implant anchorage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional intraoral anchorage
Number of subjects: 30
Study: 24969368

Group type: EXPERIMENTAL
Intervention: Jia‐Wei‐Xiao‐Yao‐San (JWXYS)
Number of subjects: 14312

Group type: EXPERIMENTAL
Intervention: Jia‐Wei‐Xiao‐Yao‐San (JWXYS) with Cyperus rotundus L.
Number of subjects: 14312

Group type: EXPERIMENTAL
Intervention: Jia‐Wei‐Xiao‐Yao‐San (JWXYS) with Leonurus heterophyllus Sweet
Number of subjects: 14312

Group type: EXPERIMENTAL
Intervention: Cyperus rotundus L. with Leonurus heterophyllus Sweet
Number of subjects: 14312
Study: 22131999

Group type: EXPERIMENTAL
Intervention: Grass Allergy Immunotherapy Tablet (AIT) with CED
Number of subjects: 261

Group type: COMPARATOR
Intervention: Grass Allergy Immunotherapy Tablet (AIT) without CED
Number of subjects: 261
Study: 20855244

Group type: EXPERIMENTAL
Intervention: Shengmai capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18763243

Group type: EXPERIMENTAL
Intervention: Titanium-coated lightweight mesh
Number of subjects: 317

Group type: COMPARATOR
Intervention: Standard polypropylene mesh
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 317
Study: 16275616

Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg/daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg/daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12594141

Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg ml(‐1) (with glucose 50 mg ml(‐1)), 3 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine 5 mg ml(‐1) (with glucose 80 mg ml(‐1)), 3 ml
Number of subjects: 40
Study: 11064438

Group type: EXPERIMENTAL
Intervention: IV administration of synthetic peptide MBP82-98 (DEN(85)VVHFFKNIVTP(96)RT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: IV saline injections every 6 months for the first 2 years
Number of subjects: 56
Study: 8759564

Group type: EXPERIMENTAL
Intervention: Ranitidine (Zantac effervescent tablets) 150 mg bd for two weeks, increased to qds for non-responders in the last two weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine (Zantac effervescent tablets)
Number of subjects: 0
Study: 1290245

Group type: EXPERIMENTAL
Intervention: Accupro monotherapy (5 mg to 40 mg daily)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Accupro combined with Diltiazem or a diuretic
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Self-recorded blood pressure measurements
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Self-recordings taken twice a day
Number of subjects: 108

Group type: COMPARATOR
Intervention: Casual office readings
Number of subjects: 108
Study: 6405494

Group type: EXPERIMENTAL
Intervention: ProcalAmine (3% amino acids, 3% glycerol, complete maintenance electrolytes)
Number of subjects: 100

Group type: COMPARATOR
Intervention: FreAmine III (isonitrogenous amino acid control solution)
Number of subjects: 100
Study: 28345961

Group type: EXPERIMENTAL
Intervention: SHUTi (Internet-based cognitive-behavioral treatment for insomnia)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Patient education (control group)
Number of subjects: 181
Study: 30501620

Group type: EXPERIMENTAL
Intervention: MCT/LCT/FO-derived n-3 PUFAs (test group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: MCT/LCT (control group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 26453051

Group type: EXPERIMENTAL
Intervention: Aggression chemosignal from boxing session
Number of subjects: 38

Group type: COMPARATOR
Intervention: Exercise chemosignal from ergometer session
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Chemosignals of aggression presented to normosmic participants
Number of subjects: 38
Study: 24391123

Group type: EXPERIMENTAL
Intervention: Video goggles (watching a favorite movie during the dental visit using sunglass-style video eyewear)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Video peer modeling (watching a DVD recording of a typically developing child undergoing a dental visit)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Video peer modeling plus video goggles
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study: 23110320

Group type: EXPERIMENTAL
Intervention: A(H1N1)pmd09 vaccine co-administered with TIV
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: A(H1N1)pmd09 vaccine sequentially administered with TIV
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pmd09 vaccine
Number of subjects: 871

Group type: COMPARATOR
Intervention: TIV
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted A(H1N1)pmd09 vaccine
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Adjuvanted A(H1N1)pmd09 vaccine
Number of subjects: 871
Study: 20594308

Group type: EXPERIMENTAL
Intervention: Six self‐management group sessions provided by a multi‐disciplinary team (occupational therapist, physiotherapist, dietician, specialized nurse) for six weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Two group sessions and four sessions by telephone provided by a specialized nurse and physiotherapist for six weeks
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Six self‐management group sessions
Number of subjects: 170

Group type: COMPARATOR
Intervention: Two group sessions and four sessions by telephone
Number of subjects: 170
Study: 17077346

Group type: COMPARATOR
Intervention: Hyperinsulinemic euglycemic clamp in healthy nonobese women
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp in insulin-resistant obese women
Number of subjects: 22
Study: 15755853

Group type: EXPERIMENTAL
Intervention: Potassium citrate (4.3 g or 40 mmol/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Calcium citrate (800 mg or 20 mmol/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combined treatment (potassium citrate and calcium citrate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12062733

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg twice daily (n = 17)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 25
Study: 11247166

Group type: EXPERIMENTAL
Intervention: Diet supplemented with PUFA omega-3 (Eiconol) 8 g/day
Number of subjects: 60
Study: 8751516

Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass system (Duraflo II)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard noncoated control system
Number of subjects: 50
Study: 1501618

Group type: EXPERIMENTAL
Intervention: Hepatoportoenterostomy (Kasai procedure)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-surgical therapy (no Kasai procedure)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 15
Study: 2859255

Group type: EXPERIMENTAL
Intervention: Combination of salbutamol plus oxatomide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Salbutamol alone
Number of subjects: 40
Study: 30885775

Group type: EXPERIMENTAL
Intervention: MRE11 protein levels assessed by immunohistochemistry (IHC) in BCON trial (n=132)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: MRE11 protein levels assessed by immunohistochemistry (IHC) in BC2001 trial (n=221)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Reoptimized staining in BCON tissue microarrays (n=116)
Number of subjects: 373
Study: 29462058

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block (USG)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Anatomical landmark technique (ALT)
Number of subjects: 72
Study: 26780408

Group type: EXPERIMENTAL
Intervention: Submaximal dose of mepivacaine 108 mg with epinephrine 54 μg (group I)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Submaximal dose of mepivacaine 216 mg with epinephrine 108 μg (group II)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 21
Study: 24629885

Group type: EXPERIMENTAL
Intervention: Mobile-based texting aftercare intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aftercare as usual control condition
Number of subjects: 80
Study: 22419500

Group type: EXPERIMENTAL
Intervention: Naturalistic longitudinal cohort study with assessments at baseline, after three and six years of follow-up.
Number of subjects: 1120
Study: 20347225

Group type: EXPERIMENTAL
Intervention: Substantial pain intensity reduction (50% pain reduction)
Number of subjects: 2575

Group type: EXPERIMENTAL
Intervention: Moderate pain intensity reduction (30% to <50% pain reduction)
Number of subjects: 2575
Study: 18055678

Group type: EXPERIMENTAL
Intervention: 3.5 g/kg per day amino acid supplementation
Number of subjects: 122

Group type: COMPARATOR
Intervention: 2.5 g/kg per day amino acid supplementation
Number of subjects: 122
Study: 15632536

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (group F, n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl combined with bupivacaine infiltration (group FB, n = 60)
Number of subjects: 120
Study: 12383453

Group type: EXPERIMENTAL
Intervention: IV catheter blood sampling
Number of subjects: 12

Group type: COMPARATOR
Intervention: Needle stick blood sampling
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IV catheter blood sampling with difficulties
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IV catheter blood sampling during sleep
Number of subjects: 12
Study: 10215955

Group type: EXPERIMENTAL
Intervention: Intranasal DDAVP (300 microg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: FVIII only
Number of subjects: 10
Study: 7486483

Group type: EXPERIMENTAL
Intervention: Ribavirin (600 mg twice daily for 12 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (for 12 months)
Number of subjects: 29
Study: 2278056

Group type: EXPERIMENTAL
Intervention: 400 mg dose of quinine, quinidine and cinchonine combination
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 500 mg dose of quinine, quinidine and cinchonine combination
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 13
Study: 31320735

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (IVD)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Systemic steroids
Number of subjects: 43
Study: 31146083

Group type: EXPERIMENTAL
Intervention: Qualitative analysis (pos/neg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Concentration ratio (CR) cut-off of 0.5
Number of subjects: 91
Study: 28240240

Group type: EXPERIMENTAL
Intervention: Toothpaste containing enzymes and proteins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 0
Study: 24799074

Group type: EXPERIMENTAL
Intervention: Perindopril erbumine (PE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Perindopril arginine (PA)
Number of subjects: 24
Study: 24138347

Group type: EXPERIMENTAL
Intervention: Positive Action (PA)
Number of subjects: 0
Study: 21449624

Group type: EXPERIMENTAL
Intervention: Drug Renal Alert Pharmacy (DRAP) program
Number of subjects: 6125

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 6125
Study: 18798228

Group type: EXPERIMENTAL
Intervention: Obesity with binge eating
Number of subjects: 374

Group type: COMPARATOR
Intervention: Obesity without binge eating
Number of subjects: 374

Group type: COMPARATOR
Intervention: Causal beliefs (psychological, biological addiction, ambiguous)
Number of subjects: 374
Study: 16902049

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg (15 mg maximum)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Normal saline (NS) placebo
Number of subjects: 166
Study: 15204056

Group type: EXPERIMENTAL
Intervention: Auditory working memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual working memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous visual and auditory working memory tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual working memory task
Number of subjects: 0
Study: 16136902

Group type: EXPERIMENTAL
Intervention: Long-term domiciliary oxygen therapy (LTDOT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (routine treatment only)
Number of subjects: 61
Study: 9597374

Group type: EXPERIMENTAL
Intervention: Metformin up to 2000 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lovastatin 40 mg daily (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 60
Study: 7871082

Group type: EXPERIMENTAL
Intervention: lorazepam 0.026 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: lorazepam 0.038 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: diazepam 0.2 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 3209284

Group type: EXPERIMENTAL
Intervention: Oral clonidine 5 micrograms kg‐1 90 min before induction of anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 40
Study: 29516486

Group type: EXPERIMENTAL
Intervention: Hydromorphone 1 mg IV
Number of subjects: 127

Group type: COMPARATOR
Intervention: Prochlorperazine 10 mg + diphenhydramine 25 mg IV
Number of subjects: 127
Study: 28409385

Group type: EXPERIMENTAL
Intervention: Dietary folic acid 1.0 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dietary folic acid 2.0 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dietary folic acid 5.0 mg/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dietary folic acid (0.0 mg/kg)
Number of subjects: 18
Study: 26213796

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Active comparison treatments
Number of subjects: 646
Study: 23579349

Group type: EXPERIMENTAL
Intervention: HF toolkit, 2 onsite meetings, and a monthly phone call
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Higher nurse-turnover
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Better practice environment
Number of subjects: 591